



RICHARD E. JENKINS
JEFFREY L. WILSON
ARLES A. TAYLOR, JR.
DAVID P. GLOEKLER
GREGORY A. HUNT
JOHN A. LAMERDIN, Ph.D.
E. ERIC MILLS
JULIE A. BROADUS, Ph.D. (PATENT AGENT)
OF COUNSEL:
JENNIFER L. SKORD

JENKINS & WILSON, P.A.
PATENT ATTORNEYS
SUITE 1400 UNIVERSITY TOWER
3100 TOWER BOULEVARD
DURHAM, NORTH CAROLINA 27707
TELEPHONE (919) 493-8000
FACSIMILE (919) 419-0383
WEBSITE
JENKINSANDWILSON.COM

RECEIVED
JAN 08 2002
#9

TECH CENTER 1600/2900

RALEIGH OFFICE
NCSU CENTENNIAL CAMPUS
VENTURE II SUITE 400
920 MAIN CAMPUS DRIVE
RALEIGH, NORTH CAROLINA 27606
TELEPHONE (919) 424-3710
FACSIMILE (919) 424-3711

October 19, 2001

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. on 10-19-01

Arly J. Martin
Date of Signature 10-19-01

Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Patent Application Serial No. 09/516,728 for MODULATION OF
ENDOTHELIAL CELL SURFACE RECEPTOR ACTIVITY IN THE
REGULATION OF ANGIOGENESIS
Our File No. 1242/12/2

Sir:

Please find enclosed in connection with the subject U.S. patent application the following documents:

1. Supplemental Information Disclosure Statement;
2. Forms PTO/SB/08A and PTO/SB/08B (in duplicate);
3. Copies of cited references (6 references);
4. A return-receipt postcard to be returned to us with the U.S. Patent and Trademark Office filing stamp thereon.

Although it is believed that no fee is due, the Commissioner is hereby authorized to charge any deficiencies of payment associated with the filing of this correspondence to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS & WILSON, P.A.

Arly A. Taylor, Jr.

Arles A. Taylor, Jr.
Registration No. 39,395
Customer No. Bar Code Label:



25297


PATENT TRADEMARK OFFICE

AAT/ajm

Enclosures

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231 on 10-19-01

Amy J. Martin
Date of Signature 10-19-01



RECEIVED
JAN 08 2002
TECH CENTER 1600/2900
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Daniel et al.

Group Art Unit: 1623

Serial No.: 09/516,728

Examiner: Bansal, G.

Filed: March 1, 2000

Docket No.: 1242/12/2 CIP

For: MODULATION OF ENDOTHELIAL CELL SURFACE RECEPTOR ACTIVITY IN THE REGULATION OF ANGIOGENESIS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. Sections 1.56, 1.97, and 1.98, the references listed below and on the attached form PTO/SB/08A are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

International Publication No. WO 00/15258 to Vanderbilt University discloses modulation of endothelial cell surface receptor activity in the regulation of angiogenesis.

Publication by Takahashi et al., "Endothelial Cell Receptor Tyrosine Phosphatase/Density Enhanced Phosphatase-1, ECRT/DEP-1, is an Oligomerization Responsive Angiostatic Switch," The FASEB Journal, Vol. 13 (No. 5), p. A694, (March 15, 1999).

Publication by de la Fuente-Garcia et al., "CD148 is a Membrane Protein Tyrosine Phosphatase Present in All Hematopoietic Lineages and is Involved in Signal Transduction on Lymphocytes," Blood, Vol. 91 (No. 8), p. 2800-2809, (April 15, 1998).

Publication by Tangye et al., "CD148: a Receptor-Type Protein Tyrosine Phosphatase Involved in the Regulation of Human T Cell Activation," The Journal of Immunology, Vol. 161 (No. 7), p. 3249-3255, (October 1, 1998).

Publication by Takahashi et al., "Endothelial Localization of Receptor Tyrosine Phosphatase, ECRT/DEP-1, Developing and Mature Renal Vasculature," The Journal of the American Society of Nephrology, Vol. 10 (No. 10), p. 2135-2145, (1999).

Publication by Stockinger et al., "New Human Leukocyte Clusters of Differentiation," Transfusion, Vol. 38 (No. 5), p. 499-505, (1998).

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the mailing of a Final Action or the Notice of Allowance. Accordingly:

☒ No \$180 fee under 37 C.F.R. Section 1.17(p) is due as the undersigned hereby certifies:

☒ that each item of information contained in this statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement, or

☐ that to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in this statement was known to any individual designated in 37 C.F.R. Section 1.56(c) more than three months prior to the filing of this statement.

☐ The undersigned is unable to so certify, because submission of the present Information Disclosure Statement is after receipt by applicant of an Official Action on the merits, and thus a check in the amount of \$180.00 is enclosed to cover the fee under 37 C.F.R. Section 1.17(p).

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO/SB/08A with initials or other appropriate marks.

Respectfully submitted,

JENKINS & WILSON, P.A.

Date: 10/19/01

By: 

Arles A. Taylor, Jr.
Registration No. 39,395

Suite 1400, University Tower
3100 Tower Boulevard
Durham, North Carolina 27707
Telephone: (919) 493-8000
Facsimile: (919) 419-0383

Customer No. Bar Code Label:



25297

1242/12/2 AAT/ajm

PATENT TRADEMARK OFFICE

Enclosures